Who are Pimicotinib(ABSK021)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NERATINIB, Herceptin, Herceptin, pertuzumab (P), Ado Trastuzumab Emtansine, TCH chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pimicotinib-absk021.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pimicotinib(ABSK021) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pimicotinib(ABSK021) (Pimicotinib(ABSK021)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2 tyrosine kinase inhibitor. Area: Oncology.

phase 3 HER2 tyrosine kinase inhibitor HER2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pimicotinib(ABSK021) (Pimicotinib(ABSK021)) — Abbisko Therapeutics Co, Ltd. Pimicotinib is a tyrosine kinase inhibitor that targets HER2 (human epidermal growth factor receptor 2) to inhibit cancer cell growth and proliferation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pimicotinib(ABSK021) TARGET	Pimicotinib(ABSK021)	Abbisko Therapeutics Co, Ltd	phase 3	HER2 tyrosine kinase inhibitor	HER2
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
Herceptin	trastuzumab	Roche	marketed	Antibody-drug conjugate (ADC)	HER2 receptor, subdomain IV	1998-01-01
Herceptin	Trastuzumab-Qyyp	Roche	marketed	HER2/neu receptor antagonist monoclonal antibody	HER2 (c-erbB2) proto-oncogene transmembrane receptor protein	1998-01-01
pertuzumab (P)	pertuzumab (P)	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	marketed	HER2 inhibitor monoclonal antibody	HER2 (human epidermal growth factor receptor 2)
Ado Trastuzumab Emtansine	Ado Trastuzumab Emtansine	Medstar Health Research Institute	marketed	Antibody-drug conjugate (ADC)	HER2 (human epidermal growth factor receptor 2)
TCH chemotherapy	TCH chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)	HER2, microtubule, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2 tyrosine kinase inhibitor class)

Abbisko Therapeutics Co, Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pimicotinib(ABSK021) — Competitive Intelligence Brief. https://druglandscape.com/ci/pimicotinib-absk021. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing